Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Therapeutic Advances in Hematology|June 2, 2017
Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective reviewOthman Al-Sawaf, Paula Cramer, Valentin Goede, et al.
The Journal of Biological Chemistry|September 11, 2002
Transcriptional activators differ in their abilities to control alternative splicingGuadalupe Nogues, Sebastian Kadener, Paula Cramer, et al.
World Journal of Gastrointestinal Endoscopy|June 15, 2016
Low volume polyethylene glycol with ascorbic acid, sodium picosulfate-magnesium citrate, and clear liquid diet alone prior to small bowel capsule endoscopyErin Rayner-Hartley, Majid Alsahafi, Paula Cramer, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|January 3, 2025
Immunoadsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders - A retrospective multicentre studyPaula Cramer, Marc Nikolaus, Sebastian Loos, et al.
IUBMB Life|July 26, 2003
Control of alternative pre-mRNA splicing by RNA Pol II elongation: faster is not always betterGuadalupe Nogués, Sebastián Kadener, Paula Cramer, et al.
Molecular Cell|October 11, 2003
A slow RNA polymerase II affects alternative splicing in vivoManuel de la Mata, Claudio R Alonso, Sebastián Kadener, et al.
Future Oncology (London, England)|July 11, 2015
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progressionPetra Langerbeins, Jasmin Bahlo, Christina Rhein, et al.
Molecular Cell|August 2, 2002
Promoter choice determines splice site selection in protocadherin alpha and gamma pre-mRNA splicingBosiljka Tasic, Christoph E Nabholz, Kristin K Baldwin, et al.
Haematologica|March 4, 2014
Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trialsValentin Goede, Paula Cramer, Raymonde Busch, et al.
Future Oncology (London, England)|February 22, 2018
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemiaPaula Cramer, Julia von Tresckow, Jasmin Bahlo, et al.
Pageof 7